Choose Your Country or Region

Annexin-2/ANXA2 Rabbit mAb

Catalog No.: F4062

Application: Reactivity: Human

Usage Information

Dilution
WB1:1000 - 1:20000 IHC1:50 - 1:100 IF1:100 - 1:250 FCM1:10 - 1:100

Application
WB, IHC, IF, FCM

Reactivity
Human

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
38 kDa

Datasheet & SDS

Biological Description

Specificity
Annexin-2/ANXA2 Rabbit mAb detects endogenous levels of total Annexin-2/ANXA2 protein.

Clone
P8A6

Synonym(s)
ANX2, ANX2L4, CAL1H, LPC2D, ANXA2, Annexin A2, Annexin II, Annexin-2, Calpactin I heavy chain, Calpactin-1 heavy chain, Chromobindin-8, Lipocortin II, Placental anticoagulant protein IV, Protein I, p36, PAP-IV

Background
Annexin-2/ANXA2 is a multifunctional, pleiotropic calcium- and anionic, phospholipid-binding protein of the annexin family that exists as a monomer or as a heterotetrameric complex (AIIt) with S100A10. Structurally, ANXA2 contains an N-terminal head domain, which undergoes post-translational modifications (acetylation, phosphorylation) and mediates interactions with S100A10, tissue plasminogen activator (tPA), and other proteins, and a conserved C-terminal core domain composed of four annexin repeats (~70 amino acids each) that bind Ca²⁺, phospholipids, heparin, RNA, and F-actin. ANXA2 is widely expressed in endothelial cells, monocytes/macrophages, neurons, and cancer cells, with expression upregulated by growth factors, oncogenes, hypoxia, and alternative splicing. Functionally, ANXA2 regulates diverse processes including exocytosis, endocytosis, membrane organization, actin cytoskeleton remodeling, redox balance, and cell surface plasmin generation (via stabilization and transport of S100A10). Its dysregulation is implicated in oncogenesis, fibrinolysis, inflammation, and neurodegenerative diseases, highlighting its pleiotropic roles in normal physiology and pathology.

Background

Annexin-2/ANXA2 is a multifunctional, pleiotropic calcium- and anionic, phospholipid-binding protein of the annexin family that exists as a monomer or as a heterotetrameric complex (AIIt) with S100A10. Structurally, ANXA2 contains an N-terminal head domain, which undergoes post-translational modifications (acetylation, phosphorylation) and mediates interactions with S100A10, tissue plasminogen activator (tPA), and other proteins, and a conserved C-terminal core domain composed of four annexin repeats (~70 amino acids each) that bind Ca²⁺, phospholipids, heparin, RNA, and F-actin. ANXA2 is widely expressed in endothelial cells, monocytes/macrophages, neurons, and cancer cells, with expression upregulated by growth factors, oncogenes, hypoxia, and alternative splicing. Functionally, ANXA2 regulates diverse processes including exocytosis, endocytosis, membrane organization, actin cytoskeleton remodeling, redox balance, and cell surface plasmin generation (via stabilization and transport of S100A10). Its dysregulation is implicated in oncogenesis, fibrinolysis, inflammation, and neurodegenerative diseases, highlighting its pleiotropic roles in normal physiology and pathology.

References
https://pubmed.ncbi.nlm.nih.gov/23519104/ https://pubmed.ncbi.nlm.nih.gov/40141747/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%